5-HTP properties - serotonin precursor for sleep and mood 2026

5-HTP, or 5-hydroxytryptophan, is sold as a natural support for mood and sleep because it is a direct precursor to serotonin. The mechanism is indeed simple and well described. However, the evidence base looks much worse: a Cochrane review found 108 studies on 5-HTP and tryptophan in depression, but only two met the methodological quality criteria, involving a total of 64 patients. Additionally, there is a risk that cannot be overlooked in consumer texts: combining 5-HTP with serotonergic medications poses a risk of serotonin syndrome, and the history of this molecule touches on an epidemic caused by contaminated raw material, which cost the lives of several dozen people in 1989. Below, we separate what has been measured from what is repeated and explain why not a single milligram figure appears throughout the text.

KEY INFORMATION
- The Cochrane review found 108 studies on 5-HTP and tryptophan in depression, but only two met the quality criteria, involving a total of 64 patients (Shaw, Cochrane Database of Systematic Reviews, 2002).
- The authors of this review state directly that since there are medications with proven efficacy and safety, the clinical usefulness of 5-HTP remains limited as of today.
- Serotonin syndrome is a potentially life-threatening condition caused by excessive stimulation of serotonergic receptors, classically through the combination of two drugs with different mechanisms (Volpi-Abadie, Ochsner Journal, 2013).
- In 1989, an epidemic of eosinophilia-myalgia syndrome due to contaminated tryptophan involved 1,531 reported cases, including 27 deaths (Swygert, JAMA, 1990).
- This text does not provide any dosage of 5-HTP in milligrams, and we explain below why we have no source for it.

What is 5-HTP and where does it come from?

5-HTP is an intermediate product of the conversion of the amino acid L-tryptophan into serotonin. It is formed from tryptophan by the addition of a hydroxyl group and then undergoes decarboxylation to serotonin. As a supplement, it bypasses the first step of this pathway, which is the reaction catalyzed by tryptophan hydroxylase, which limits the rate of the entire pathway (Birdsall, Alternative Medicine Review, 1998).

Two features distinguish it from tryptophan itself, and these are behind the popularity of this molecule. The absorption of 5-HTP from the intestine does not require a transport molecule and does not depend on the presence of other amino acids, so the preparation can be taken with a meal without losing effectiveness. Meanwhile, tryptophan can be directed towards niacin production or incorporated into protein, and 5-HTP does not have that option.

The commercial raw material comes from the seeds of an African shrub Griffonia simplicifolia. Chemical analysis of the seeds using HPLC with mass detection confirms that 5-HTP is the most abundantly represented compound in them, followed by the beta-carboline alkaloid griffonia and other alkaloids (Vigliante, Molecules, 2019).

The same study describes why it was created: to provide a method for unequivocal identification of commercial seeds. The authors combined chemical analysis with DNA profiling, obtaining a restriction pattern that allows confirmation that the raw material comes from the correct plant. The existence of such a tool speaks volumes about the state of the herbal raw materials market.

How does the body convert 5-HTP into serotonin?

Through a single enzymatic reaction, but the location where it occurs determines everything. The conversion is mediated by aromatic amino acid decarboxylase, and the amount of 5-HTP reaching the central nervous system depends on how much of it has been converted into serotonin in the periphery before crossing the blood-brain barrier (Turner, Pharmacology and Therapeutics, 2006).

This distinction has a consequence that is lost in product descriptions. Serotonin produced outside the brain does not affect mood because it cannot cross the blood-brain barrier. However, it acts in the gastrointestinal tract and the circulatory system, which explains why the first noticeable effect of 5-HTP may be gastrointestinal discomfort rather than a change in mood.

In studies on this phenomenon, peripheral decarboxylase inhibitors, such as carbidopa, are used, which block the conversion outside the brain and thus increase the pool reaching the central nervous system. A supplement bought off the shelf does not contain such an inhibitor, so part of the dose taken never reaches where it should act.

How much of it reaches there is not precisely known. A review from 1998 states that about 70% of the oral dose reaches the bloodstream and that 5-HTP easily crosses the blood-brain barrier, increasing serotonin production in the central nervous system. Serotonin itself regulates sleep, mood, anxiety, appetite, body temperature, and pain perception, so increasing its pool is not a targeted action.

It's also worth knowing what happens to tryptophan before it even becomes 5-HTP. Besides tryptophan hydroxylase, two other enzymes compete for this same amino acid: indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase. They direct tryptophan down a completely different metabolic pathway, and their activity increases, among other things, in inflammatory states.

This is where the argument for supplementing 5-HTP instead of tryptophan comes from. Administering ready-made 5-HTP bypasses all this competition. However, it does not bypass the peripheral decarboxylation described above, so one bottleneck replaces another, and the review discussing the factors influencing each of these enzymes points this out as an area requiring attention.

What do studies on 5-HTP in depression really show?

That there is a signal, but the evidence underneath is crumbling. The Cochrane review searched databases for randomized studies comparing 5-HTP or tryptophan with placebo in people with unipolar depression and dysthymia. It found 108 studies. Only two met the sufficient quality criteria for inclusion, involving a total of 64 patients (Shaw, Cochrane Database of Systematic Reviews, 2002).

The result from these two studies favored the supplement: the odds ratio using the Peto method was 4.10 with a confidence interval from 1.28 to 13.15, and the number of patients needed to treat for one additional effect was 2.78. However, the width of this interval says as much as its position. With 64 people, the estimate is shaky.

The authors' conclusions are twofold, and both are worth knowing. First: a large number of studies seemingly relates to the posed question, but few are reliable enough to depend on. Second, and more severe: since there are antidepressants with proven efficacy and safety, the clinical usefulness of 5-HTP and tryptophan remains limited as of today.

Where does the optimism circulating in the market come from? From Birdsall's 1998 review, which describes 5-HTP as a clinically effective serotonin precursor and lists depression, fibromyalgia, binge eating in obesity, chronic headaches, and insomnia as conditions where administering 5-HTP has proven effective. These two sources are not contradictory. Birdsall shows a signal, Cochrane shows that the signal has not been confirmed by modern-class studies.

There is one more detail in this review that rarely makes it into market summaries, and it changes the interpretation of the result. Due to the small number of included studies, the authors had to combine the analysis for 5-HTP and tryptophan into one. Therefore, the favorable result does not pertain solely to 5-HTP, but to both precursors treated together.

The review itself was conducted thoroughly, making its result harder to dismiss. Studies were sought in general and specialized databases, bibliographies of related works were reviewed, industry journals were manually searched, and authors were contacted, with publications sought in all languages. The quality of studies was assessed for the risk of systematic error. With such effort, filtering down to two works is not a result of oversight but a reflection of the state of the literature.

Does 5-HTP help with sleep?

The honest answer is: we do not have good data on this. The Cochrane review, which is the sharpest available filter here, only concerned depression, so it did not assess sleep at all. However, insomnia appears on the list of conditions mentioned by Birdsall as those in which administering 5-HTP has proven effective, and that is all the material we have here (Birdsall, Alternative Medicine Review, 1998).

This is too little to make a statement about effectiveness. The 1998 review summarizes older literature, mostly from before the era of rigorous double-blind studies, and in the same field, a newer Cochrane review showed how small a portion of such contributions withstands stricter criteria. Assuming that it would be different for sleep has no basis.

It is worth understanding how 5-HTP differs from melatonin, as these two substances are often compared as substitutes. Melatonin is produced from serotonin in the pineal gland and is a ready signaling molecule acting on its own receptors. 5-HTP is a substrate, located two stages earlier in the transformation, and its effect on sleep depends on what the body does with this substrate. We write about this separately in the text about how melatonin affects sleep.

If you are looking for sleep support, this distinction is practical. A substance with a documented mechanism and studies on specific applications ranks higher than a substance whose mechanism is described, but its application is poorly studied. Insomnia lasting for months is, after all, a reason to visit a doctor, not to shop.

Why should 5-HTP not be combined with antidepressants?

Because it risks serotonin syndrome, a potentially life-threatening condition. It is triggered by excessive stimulation of peripheral and central postsynaptic 5-HT1A receptors, and primarily 5-HT2A. A characteristic picture emerges: disturbances in mental state, excessive neuromuscular excitability, and hyperactivity of the autonomic nervous system (Volpi-Abadie, Ochsner Journal, 2013).

The authors of this review describe three pathways to serotonin syndrome. It can occur with the therapeutic use of serotoninergic drugs alone, from intentional overdose, but it classically arises from a complex interaction of two serotoninergic substances acting through different mechanisms. The last scenario precisely describes the situation where someone adds a supplement to ongoing pharmacotherapy.

This risk is explicitly mentioned in the literature on 5-HTP itself. A pharmacological review dedicated to supplementation with this molecule discusses safety issues with particular emphasis on two: eosinophilia-myalgia syndrome and serotonin syndrome (Turner, Pharmacology and Therapeutics, 2006). This is not excessive caution, but rather the two most frequently discussed risks of this substance.

The practical rule is short and does not require a list of brand names. If you are taking any medication affecting serotoninergic transmission, the decision about 5-HTP should be made by the attending physician or clinical pharmacist, not an internet forum. Do not discontinue your medication on your own to make room for the supplement. We discuss this group of interactions more broadly in the text about przeciwwskazaniach i zespole serotoninowym.

The authors of the review point out something that speaks more strongly for this caution than a list of prohibitions. Many commonly used medications are responsible for serotonin syndrome, and the number of possible combinations that can trigger it is large. Therefore, it is difficult to assume in advance that our particular set of preparations is safe, as recognizing this risk can also be challenging for doctors.

The goal that the authors set for their review is, in fact, straightforward: to alert doctors to this syndrome, as it is potentially fatal yet avoidable. Proper knowledge and vigilance improve diagnostic accuracy and allow for early treatment implementation. For the reader, this means one thing: discussing the supplement with someone who knows the entire list of medications they are taking is not a formality.

What was the eosinophilia-myalgia syndrome?

An epidemic from 1989 that permanently changed the status of serotonin precursors in the supplement market. Eosinophilia-myalgia syndrome was diagnosed based on debilitating muscle pain and an absolute eosinophil count of at least one billion cells per liter of blood. By July 10, 1990, 1531 cases had been reported in the United States, including 27 deaths (Swygert, JAMA, 1990).

The disease picture was multi-organ. The most common symptoms included joint pain in 73% of patients, rash in 60%, cough or shortness of breath in 59%, and peripheral edema in 59%. Elevated aldolase levels were noted in 46%, and abnormal liver function tests in 43%. Neuropathy or neuritis occurred in 27%, leading to paralysis and death in some patients. In 21% of those undergoing chest radiography, abnormalities were found.

The cases were not evenly distributed. The highest rates were recorded in western states, and 68% of patients were white women who were not of Hispanic origin, aged 35 and older. This profile, clearly deviating from the distribution in the general population, itself directed suspicion towards a specific product consumed by a particular group.

The connection with the product was clear. In 91% of patients, symptoms appeared in May 1989 or later, and 97% had previously taken tryptophan. After the withdrawal of tryptophan products from free sale in November 1989, the number of new cases sharply declined, which in itself is a strong argument for causality.

This story concerns tryptophan, not 5-HTP, and this distinction is often used in marketing materials as an argument that 5-HTP is not implicated in the episode. The Cochrane review from 2002 states this more cautiously: the possible connection between these substances and the potentially fatal eosinophilia-myalgia syndrome has not been clarified. However, 'not clarified' is not the same as 'excluded.'

Are today's 5-HTP preparations free from contaminants?

The study that checked this responds disturbingly. Researchers determined the chemical structure of a contaminant labeled as Peak X, previously found in 5-HTP preparations associated with cases of eosinophilia and myalgia. It turned out to be 4,5-tryptophanodione, a compound considered a potential neurotoxin (Klarskov, The Journal of Rheumatology, 2003).

However, the second part of this result is the most important. The substance was found not only in material related to illnesses but in all six tested samples of 5-HTP available for sale. Its content in these samples ranged from 0.5% to 10.3% of the amount present in the material associated with the disease cases.

The authors' conclusion is stated plainly: this raises some concerns about the safety of such commercial 5-HTP preparations. We noticed that in Polish descriptions of this issue, this statement is often reversed into a reassuring message, such as "today reputable suppliers are testing the raw material for the presence of Peak X." The work they refer to does not say anything like that.

The methodology of this work deserves attention because it explains why the result is difficult to dispute. The samples were subjected to high-precision mass spectrometry coupled with liquid chromatography and electrochemical detection, a reaction with reduced glutathione was conducted, and the obtained spectra were compared with the spectra of the standard 4,5-tryptophanodione. Therefore, the identification is not based on retention time similarity but on comparison with the standard substance.

What does this work not resolve? It studied samples available at the time of its creation, so it does not answer the question about today's supply chains. This is a real gap, not an excuse: we did not find a newer study that would repeat this measurement on the current market. The analysis certificate for a specific batch is, in this situation, not so much an addition as the only information that the buyer can obtain.

Why won't you find dosages in this text?

Because after checking the sources, it turned out that we have no basis for them. An earlier version of this article provided several ranges in milligrams, separately for mood, sleep, migraine, and fibromyalgia, along with a detailed starting protocol. Each of these ranges led either to the homepage of the institution instead of a specific document or to a study whose summary does not contain any of those numbers.

We checked this step by step. The summary of the 1998 Birdsall review does not provide a dosage range. The summary of the 2002 Cochrane review also does not provide them, as it describes the number of studies and the quality of evidence, not the administration scheme. Thus, there are zero verified numbers, and a number that cannot be pointed out at the source is no different from an invented one.

The second reason is more serious than the lack of data. A dosage given to a reader who is concurrently taking a serotoninergic drug is an invitation to exactly the interaction that this article warns against. With a substance whose main documented risk is a reaction to a combination with a drug, the number in the text works against the intention.

What to do about this in practice? If you are considering 5-HTP, determine the portion size with your doctor or pharmacist, having a list of everything you take regularly, including over-the-counter preparations. This is the same conversation that will simultaneously catch contraindications, so it is not an additional obstacle, but the only sensible first step.

What else affects mood and sleep?

Things with a clearly stronger evidence base than any serotoninergic supplement. A meta-analysis of 49 prospective studies involving 266,939 people observed for a total of over 1.8 million person-years showed that individuals with high levels of physical activity had a lower chance of developing depression than those with low activity, with an odds ratio of 0.83 (Schuch, The American Journal of Psychiatry, 2018).

The protective effect persisted in every age group studied: among adolescents, adults, and older individuals, as well as in all analyzed regions of the world. The authors did not identify any factor that modified it. This is a rare situation in epidemiology and speaks more than a single interventional study.

The authors also checked the robustness of their result. The relationship persisted separately for a positive screening result for depressive symptoms and separately for the diagnosis of severe depression, and the quality of the included studies was rated as moderate to high. A significant publication bias was detected, but after accounting for it, the strength of the association did not change.

On the treatment side, the picture is equally clear. A network meta-analysis of 331 randomized studies involving 34,285 patients showed that all major types of psychotherapy for depression are more effective than usual care and waiting lists, and individual methods do not differ significantly from each other, with one exception (Cuijpers, World Psychiatry, 2021). Most of them maintained a significant effect even after twelve months of observation.

The range of effect sizes compared to usual care ranged from 0.81 standard deviations for life review therapy to 0.32 for non-directive supportive counseling, and the results did not change after limiting the analysis to studies with low risk of systematic error. With one exception, the methods did not differ from each other, so the choice may depend on availability and patient preference.

A supplement will not replace either of these two things, and it's worth stating this clearly before adding another jar to the shelf. If you are still looking for preparations that support the nervous system, you can find their overview in the category supplements, but treat them as a complement to a course of action that has stronger evidence.

Frequently Asked Questions

What is 5-HTP and why is it called the serotonin precursor?

It is an intermediate product of the conversion of L-tryptophan to serotonin. As a supplement, it bypasses the first step of this pathway, which is the reaction catalyzed by tryptophan hydroxylase, which limits the rate of the entire pathway, and provides a ready substrate for aromatic amino acid decarboxylase (Birdsall, Alternative Medicine Review, 1998).

Can 5-HTP be combined with antidepressants?

Not on your own. Serotonin syndrome classically arises from the interaction of two serotoninergic substances acting through different mechanisms and is a potentially life-threatening condition (Volpi-Abadie, Ochsner Journal, 2013). The decision to combine them is made by the attending physician or clinical pharmacist.

Does 5-HTP work for depression?

The Cochrane review found 108 studies, of which two met quality criteria, involving 64 patients. The outcome favored the supplement, but the authors deemed the evidence insufficient to be conclusive and pointed out the existence of drugs with proven efficacy (Shaw, Cochrane Database of Systematic Reviews, 2002).

How much 5-HTP should be taken?

This text cannot be honestly concluded with a number. The summaries of both main reviews on which knowledge about this molecule is based do not provide a dosage range, and a number that is not confirmed by the source is no different from an invented one. Determine the portion size with your doctor or pharmacist.

What was the eosinophilia-myalgia syndrome?

An epidemic from 1989 following contaminated tryptophan. By July 10, 1990, 1531 cases had been reported, including 27 deaths, and after the withdrawal of products from free sale in November 1989, the number of new cases dropped sharply (Swygert, JAMA, 1990).

Are commercial 5-HTP products pure?

The study that examined this found contamination of Peak X, or 4.5-tryptophanodione, in all six tested samples available for sale, with amounts ranging from 0.5% to 10.3% content in materials associated with illnesses. The authors considered this a cause for concern (Klarskov, The Journal of Rheumatology, 2003).

How does 5-HTP differ from melatonin?

Melatonin is produced from serotonin and is a ready signaling molecule acting on its own receptors. 5-HTP is a substrate that lies two transformation steps earlier, so its effect depends on what the body does with this substrate. This is the difference between a finished product and a raw material.

What follows from this

5-HTP has a simple mechanism and a weak evidence base, and this combination lends itself to promises. The molecule indeed bypasses the limiting step of serotonin synthesis and does cross the blood-brain barrier. However, this does not imply a clinical effect, as the question of the relationship between a correct mechanism and proven action lies in studies, not in a scheme of transformations.

The answer from the studies is known and uncomfortable. Of the 108 works found by the Cochrane review, two passed the quality assessment, involving 64 patients. The result was favorable, the confidence interval very wide, and the authors' conclusion unambiguous: given the existence of drugs with proven efficacy, the clinical usefulness of this substance remains limited as of today.

On the risk side, we have two specific items. Combining with a serotoninergic drug poses a risk of serotonin syndrome, which can be life-threatening. Peak X contamination was found in all six tested samples available for sale, and the authors of this work called it a basis for concern, not a historical curiosity.

The practical conclusion is therefore less flashy than a dosage table, but it is true. If you are struggling with a low mood or insomnia lasting for weeks, the first step leads to a doctor, not to a store. If you still want to try 5-HTP, do so after talking to your doctor or pharmacist, with a complete list of medications in hand. In case of suicidal thoughts, call 116 123, and in an emergency, dial 112.

This article is for informational and educational purposes and does not constitute medical advice. Before starting supplementation, consult your doctor, especially if you are taking medications regularly, are pregnant or breastfeeding, or have a chronic illness.

Author: Michał Waluk · Opublikowano: 2026-05-11 · Aktualizacja: 2026-08-10